Previous studies have identified recurrent somatic mutations in epigenetic regulators in patients whose disease has transformed from MPN to AML, including mutations in isocitrate dehydrogenase 1 (IDH1), IDH2, and TET2 (9, 10). This evidence concerns the gene IDH2 and myeloproliferative disorder.